ReViral
ReViral is a UK-based clinical-stage biotechnology company founded in 2011 that develops antiviral therapies for patients, having raised approximately $121 million across four private funding rounds from 2014 to 2020.
- Company typePrivate
- Founded2011
- HeadquartersStevenage, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ReViral does
ReViral is a privately held clinical-stage biotechnology company founded in 2011 and headquartered in Stevenage, United Kingdom. The company develops antiviral therapies intended for patient treatment, with the available context indicating a focus on respiratory viral infections. Operating with a small team of 11-50 employees, ReViral follows a development-stage biotech model centered on proprietary antiviral compounds advancing through clinical evaluation, rather than a commercial-stage pharmaceutical sales operation.
The company has financed its R&D through four private funding rounds between December 2014 and August 2020, raising approximately $121 million in total. Investor participation has included a consistent group of healthcare-focused institutional investors: Brace Pharma, Andera Partners, New Leaf Venture Partners, Novo Holdings/Ventures, OrbiMed, and Perceptive Advisors, with CR-CP Life Science Fund and Green Sands Equity joining the 2020 syndicate. The funding progression — from a $1M initial round (2014) to a $21M round (2015), a $55M Series B (2018), and a $44M Series C (2020) — signals sustained institutional confidence and a pipeline advancing through progressively more capital-intensive clinical stages.
Leadership combines founder-led scientific direction with experienced pharma executives. Co-founders Stuart Cockerill (Chief Scientific Officer) and Neil Mathews (Project Director) provide continuity of the original research vision, while Ken Powell serves as Executive Chairman and Brett Haumann as Chief Medical Officer. The business model is consistent with a clinical-stage biotech: no listed commercial products, no disclosed pricing, and revenue generation contingent on future regulatory approval, commercialization, or partnership/licensing. The supplied data does not include source-resolvable information on post-2020 corporate status.
ReViral firmographics
Firmographics- Name
- ReViral
- Website
- https://reviral.co.uk
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 11–50 employees
- Short description
- ReViral is a UK-based clinical-stage biotechnology company founded in 2011 that develops antiviral therapies for patients, having raised approximately $121 million across four private funding rounds from 2014 to 2020.
- Ownership category
- akta.pro rank
ReViral industry classification
Industry- Product category
- Antiviral Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where ReViral is headquartered
LocationHeadquarters
- HQ city
- Stevenage
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
ReViral business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
ReViral product offering
Product offeringCore offering
ReViral is a clinical-stage biotechnology company that discovers and develops antiviral drug candidates targeting respiratory syncytial virus (RSV). The company's portfolio includes small-molecule fusion inhibitors and other antiviral agents intended to treat and prevent RSV infections in at-risk populations. ReViral operates primarily in the drug discovery and clinical development phases of pharmaceutical R&D.
Product overview
No product information available for ReViral in the source data. The domain reviral.co.uk contains content about a gambling/casino review website (Non GamStop Casinos), not a technology company. The other sources contain unrelated content about Pfizer and Innovent Biologics partnership, or blocked/error pages.
Differentiator
Problem solved
Functional benefit
Products and services
- RSV fusion inhibitor (lead clinical candidate)
- RSV antiviral discovery platform
Companies that use ReViral
Customer profileIdeal customer profiles2 records
ReViral technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ReViral partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
ReViral competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights5 records
Customer concentration
ReViral social profiles
Digital presenceReViral financial estimates
Financial estimateRevenue estimate
Valuation estimate
ReViral leadership team
Management profileNumber of profiles
Profiles4 records
ReViral funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ReViral M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ReViral
What does ReViral do?
ReViral is a clinical-stage biotechnology company that discovers and develops antiviral drug candidates targeting respiratory syncytial virus (RSV). The company's portfolio includes small-molecule fusion inhibitors and other antiviral agents intended to treat and prevent RSV infections in at-risk populations. ReViral operates primarily in the drug discovery and clinical development phases of pharmaceutical R&D.
When was ReViral founded?
ReViral was founded in 2011. It employs 11 to 50 people.
Where is ReViral based?
ReViral is headquartered in Stevenage, United Kingdom, in the Europe region.
Does ReViral have an API?
No public API is recorded for ReViral.
What industry is ReViral in?
ReViral's product category is Antiviral Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 541714.